Kinase Inhibitor Drug Class List

Drugs in Drug Class: Kinase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-001	Mar 30, 2009	AB	RX	Yes	Yes	9,006,224
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-001	Mar 30, 2009	AB	RX	Yes	Yes	8,410,131*PED				Y
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-004	Mar 30, 2012	AB	RX	Yes	No	9,006,224
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-004	Mar 30, 2012	AB	RX	Yes	No	8,410,131*PED				Y
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-002	Mar 30, 2009	AB	RX	Yes	No	9,006,224
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-002	Mar 30, 2009	AB	RX	Yes	No	8,410,131*PED				Y
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-003	Jul 9, 2010	AB	RX	Yes	No	9,006,224

Kinase Inhibitor Market Analysis and Financial Projection

The kinase inhibitors market is undergoing rapid transformation, driven by scientific breakthroughs and shifting intellectual property dynamics. Valued at $58.1 billion in 2023, the sector is projected to reach $89.9 billion by 2034 (3.9% CAGR)[1][12], with some estimates forecasting even stronger growth up to $104.2 billion by 2030 (9% CAGR)[12][9]. This expansion reflects both therapeutic advancements and complex patent strategies shaping market competition.

Key Market Drivers and Therapeutic Innovations

Breakthrough Therapy Development has been accelerated by:

• Precision oncology: 23% of recent FDA approvals target genetic biomarkers[9]
• Expanding applications: From 85% oncology focus in 2015 to growing autoimmune/inflammatory disease applications[1][5]
• Next-gen compounds: MEK kinase inhibitors like Kinnate Biopharma's phosphane oxides entering trials (US20230416286A1)[3]

Commercial Momentum stems from:

• Rising cancer prevalence: Projected 77% global increase (20M→35M cases) by 2050[12]
• Autoimmune disease growth: 8M+ psoriasis patients in US alone driving JAK inhibitor demand[5]

Patent Landscape and Genericization Timeline

The intellectual property arena shows strategic maneuvering:

Patent Trend	Impact	Timeline
New Filings Surge	1,915 applications in 2018 alone[2]	40% of all kinase patents filed 2013-2018[2]
Key Expirations	19 PKIs generic by 2025[11]	Imatinib exclusivity extended to 2029[6]
Therapeutic Expansion	145 kinase targets under development vs 627 unexplored[10]	48 PKIs expected generic by 2030[11]

Pharma companies counter generic erosion through:

• Patent evergreening: Vemurafenib achieved 18-year exclusivity via formulation patents[6]
• Combination therapies: 68% of recent trials pair kinase inhibitors with immunotherapies[1]

Regional Market Dynamics

North America Dominance (48% market share)[9] persists due to:

• $2.3B average drug development costs enabling premium pricing
• 72% of orphan drug designations for kinase inhibitors[9]

Asia-Pacific Growth (9.7% CAGR)[12] fueled by:

• China's NMPA approving 14 kinase inhibitors in 2024 alone
• Indian generics capturing 28% post-patent market share[11]

Challenges Shaping Future Development

The sector faces dual pressures:

• Scientific Hurdles

  • 63% of patients develop resistance within 24 months[9]
  • Off-target effects in 42% of first-gen inhibitors[1]

• Commercial Pressures

  • $2.8M avg. cost per patient annually[12]
  • 38% R&D budget allocation to combination therapies[8]

Regulatory Complexity intensifies with:

• 22-month average FDA review time for new kinase drugs[9]
• 57% of trials requiring companion diagnostics[12]

---

"The next decade will see kinase inhibitors transition from blockbuster monotherapies to component parts of precision medicine cocktails." - Transparency Market Research[1]

As the market evolves, companies combining robust patent strategies with AI-driven discovery (like Insilico's DDR1 inhibitors)[8] are poised to lead. However, the coming patent cliff (48% drugs generic by 2030)[11] ensures fierce competition between innovators and generics manufacturers, potentially improving global access to these targeted therapies.

References

1. https://www.globenewswire.com/news-release/2025/02/13/3025961/32656/en/Kinase-Inhibitors-Market-to-Surge-from-USD-58-Billion-in-2023-to-USD-89-9-Billion-by-2034-Fueled-by-Targeted-Therapy-Breakthroughs-and-Cancer-Prevalence-Latest-Report-by-TMR.html
2. https://caldwelllaw.com/news/protein-kinase-inhibitors-inventing-new-patent-strategies/
3. https://www.pharmaceutical-technology.com/data-insights/kinnate-biopharma-files-patent-for-inhibitors-of-mek-kinase-for-disease-treatment/
4. https://www.globenewswire.com/news-release/2023/03/15/2627805/0/en/Global-Kinase-Inhibitors-Market-Size-To-Grow-USD-95-3-Billion-By-2030-CAGR-of-7-3.html
5. https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report
6. https://gabi-journal.net/overview-of-the-patent-expiry-of-non-tyrosine-kinase-inhibitors-approved-for-clinical-use-in-the-eu-and-usa.html
7. https://patents.google.com/patent/US8741849B2/en
8. https://www.databridgemarketresearch.com/reports/global-kinase-inhibitors-market
9. https://www.verifiedmarketresearch.com/product/kinase-inhibitors-market/
10. https://www.technologynetworks.com/neuroscience/news/drug-discovery-focus-on-small-molecule-kinase-inhibitors-192885
11. https://pubmed.ncbi.nlm.nih.gov/34451807/
12. https://www.nextmsc.com/report/kinase-inhibitors-market